Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA E545K |
Therapy | Alpelisib + Toripalimab-tpzi |
Indication/Tumor Type | cervical cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545K | cervical cancer | sensitive | Alpelisib + Toripalimab-tpzi | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Piqray (alpelisib) and Loqtorz (toripalimab-tpzi) inhibited proliferation in cell line xenograft models of cervical cancer harboring PIK3CA E545K and in a patient-derived xenograft (PDX) model (PMID: 37469254). | 37469254 |
PubMed Id | Reference Title | Details |
---|---|---|
(37469254) | Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer. | Full reference... |